Singapore Expansion Supports Growing Healthcare and Pharma Markets

West Pharmaceutical Services, Inc, a global leader in innovative solutions for injectable drug administration, has officially opened its state-of-the-art manufacturing facility in Jurong, Singapore. This investment is part of West's commitment to a global investment of over US$350 million in 2023, primarily focused on expanding capacity and meeting the increasing demand for their products and services in the pharmaceutical industry, particularly for sensitive and complex molecules in compliance with evolving regulatory standards.

The establishment of the Jurong facility comes at a crucial time when the advancement of biologics is transforming disease prevention, diagnosis, and treatment. This facility enables West to fulfil its customers' needs by offering high-quality containment products for injectable drugs in a single location within the Asia Pacific region, thereby reducing overall lead times for customers.

To cater to future demand, West has significantly expanded the Jurong facility, which now spans 18,000 m². It is equipped with cutting-edge coating, pharmaceutical washing, sterilisation, and automated vision inspection capabilities for elastomers. These advancements minimise the risk of contamination and ensure compatibility with packaging components. Additionally, new moulding and compounding equipment with improved energy efficiency and automation capabilities have been installed.

With these enhancements, West's Jurong facility has the capacity to manufacture a comprehensive range of advanced containment products, including components with Westar™ Select quality level, Envision™ verification process, and FluroTec™ barrier film. This expansion addresses the healthcare industry's increasing focus on biologics, such as cell and gene therapeutics, while providing customers with enhanced on-the-ground technical support.

Eric Green, President, CEO, and Chair of the Board of Directors at West, stated: "As we celebrate West's 100th anniversary this year, we remain dedicated to strengthening our global networks to address the critical changes in healthcare and drug delivery. The investment in our Jurong facility plays a pivotal role in fulfilling our purpose of providing customers and patients worldwide with access to essential medicines."

West currently employs over 600 people across three locations in Singapore, including the JTC Summit Office, the Jurong plant, and the Gemini laboratory. The investment has already created more than 200 new jobs, and an additional 40 roles are expected to be added by the end of 2023.

More information online